Purchase this article with an account.
M. Hu, G. Huang, F. Karasina, V. G. Wong; VerisomeTM, a Novel injectable, Sustained Release, Biodegradable, Intraocular Drug Delivery System and Triamcinolone Acetonide. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5627.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
An injectable, sustained release, biodegradable drug delivery system is needed to optimally treat a wide variety of ophthalmic diseases. Many non-biodegradable triamcinolone acetonide (TA) implants which require sutures or surgical procedures have been reported. The authors evaluated the feasibility of VerisomeTM for the sustained release of TA.
Two (2) VerisomeTM formulations containing triamcinolone acetonide (TA) 6.9 mg and 13.8 mg were injected into two groups of NZW rabbit vitreous, and drug levels were measured over a period of one (1) year. Drug toxicity was assessed over this same time period by ophthalmic examination and histologic examination.
The group injected with 6.9 mg of TA demonstrated sustained levels of TA in the vitreous for up to 6 months. The mean TA vitreous level was 1.5 µg/mL. Similarly, the group initially injected with 13.8 mg TA showed sustained levels of TA in the vitreous for up to one (1) year. The mean TA vitreous level was 1.1 µg/mL. There was no evidence of toxicity as determined by clinical examination and histologic examination.
VerisomeTM is an injectable, biodegradable and effective delivery system for sustained intraocular administration of triamcinolone acetonide. The system appears well tolerated in the rabbit eye.
This PDF is available to Subscribers Only